Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

821.96 -11.58 (-1.39%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

November 01, 2024

Via Benzinga

This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

November 01, 2024

Via Benzinga

The Latest Analyst Ratings For argenx ↗

October 17, 2024

Via Benzinga

Biotech Stocks : Are You A Trader Or A Longer Term Investor? ↗

October 01, 2024

Biotech bull market is intact as indicated by large cap biopharma and the best performing funds.

Via Talk Markets

Peeling Back The Layers: Exploring argenx Through Analyst Insights ↗

September 26, 2024

Via Benzinga

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗

September 25, 2024

Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.

Via Investor's Business Daily

What 25 Analyst Ratings Have To Say About argenx ↗

August 23, 2024

Via Benzinga

The Analyst Verdict: argenx In The Eyes Of 27 Experts ↗

July 29, 2024

Via Benzinga

Breaking Down argenx: 12 Analysts Share Their Views ↗

May 10, 2024

Via Benzinga

Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 24, 2024

Via Benzinga

Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB ↗

August 29, 2024

Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 12, 2024

Via Benzinga

This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

August 06, 2024

Via Benzinga

The Analyst Verdict: argenx In The Eyes Of 12 Experts ↗

April 18, 2024

Via Benzinga

Key Takeaways From argenx Analyst Ratings ↗

March 26, 2024

Via Benzinga

Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday ↗

July 29, 2024

Via Benzinga

Why Is European Drugmaker Argenx Stock Trading Higher On Monday? ↗

June 24, 2024

The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030.

Via Benzinga

Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval ↗

June 24, 2024

This is the second approval for the biotech company's drug, Vyvgart Hytrulo.

Via Investor's Business Daily

Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday ↗

June 24, 2024

Via Benzinga

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 24, 2024

Via Benzinga

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay ↗

May 30, 2024

Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday.

Via Investor's Business Daily

Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study ↗

May 29, 2024

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

Via Benzinga

Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump ↗

May 29, 2024

The company says it's still running additional testing of the drug, calling the results "positive."

Via Investor's Business Daily

Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗

May 09, 2024

Via Benzinga

ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

ARGX stock results show that argenx missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

May 09, 2024

Via Benzinga

Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

May 09, 2024

Via Benzinga

Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy ↗

April 10, 2024

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current...

Via Benzinga

Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 26, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 21, 2024

Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

argenx SE - American Depositary Shares (NQ:ARGX)

Headline News about argenx SE - American Depositary Shares

Starting at $3.75/week.

Subscribe Today